RxDoctor Payments Data

Ali Khan, MD

Hospitalist · Syracuse, NYNPI 1588985782

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 315 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,128, 8.7 times the $246 reported in 2021. Among hospitalist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,008in general payments, 2019–2025

Across 315 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$742
  • AbbVie$676
  • GSK$623
  • Novo Nordisk$568
  • Viiv Healthcare Company$506
  • Pfizer$404
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$6,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,008 in reported general payments places this provider in the 95th percentile of 1,860 hospitalist providers in New York.

See all hospitalist providers in New York

Medicare billing

Part B allowed, 2024
$164,790
Medicare patients
523
Services billed
3,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$56,435
XareltoRivaroxaban31$43,545
OzempicSemaglutide29$41,851
TrulicityDulaglutide32$38,110
JanuviaSitagliptin Phosphate19$26,856
JardianceEmpagliflozin23$22,043
FarxigaDapagliflozin Propanediol18$21,575
CaplytaLumateperone Tosylate11$18,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,761
VraylarCariprazine Hcl12$16,334
Breo ElliptaFluticasone/Vilanterol15$13,014
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,988
VascepaIcosapent Ethyl14$4,974
Levothyroxine Sodium175$4,460
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$404$56,43553 claims
Johnson & JohnsonXarelto$318$43,54531 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$623$42,92774 claims
Novo NordiskOzempic$568$41,85129 claims
Lilly USA, LLCTrulicity$131$38,11032 claims
MerckJanuvia$86$26,85619 claims
Boehringer IngelheimJardiance$45$22,04323 claims
AstraZenecaFarxiga$360$21,57518 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$54$18,85611 claims
AbbVieVraylar, Synthroid$676$17,30733 claims
Sanofi-aventis U.S. LLCLantus$99$72212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,860 hospitalist providers in New York.

Other hospitalist in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →